AbbVie Inc. - notizie pubblicate 394 - letture 16.043


AbbVie Inc.

ABBVIE INC.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

07.05.2024
AbbVie Inc.

ABBVIE INC.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

07.05.2024
AbbVie Inc.

ABBVIE INC.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

07.05.2024
AbbVie Inc.

ABBVIE INC.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

07.05.2024
AbbVie Inc.

ABBVIE INC.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

07.05.2024
AbbVie Inc.

ABBVIE INC.

AbbVie to Present at the Bank of America Securities Healthcare Conference

Corporate news may 06, 2024 abbvie to present at the bank of america securities healthcare conference open a printable version of this page email the url of this page to a friend n ...

06.05.2024
AbbVie Inc.

ABBVIE INC.

Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)

Abbv-20240331 united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☒quarterly report pursuant to section 13 or 15(d) of the securities exc ...

03.05.2024
AbbVie Inc.

ABBVIE INC.

AbbVie Reinforces Commitment to Science and Innovation with a €150 million Euro Investment in New Cutting-Edge Research and Development Facility in Germany

April 30, 2024 abbvie reinforces commitment to science and innovation with a €150 million euro investment in new cutting-edge research and development facility in germany open a ...

30.04.2024
AbbVie Inc.

ABBVIE INC.

AbbVie Reports First-Quarter 2024 Financial Results

Corporate news april 26, 2024 abbvie reports first-quarter 2024 financial results open a printable version of this page email the url of this page to a friend reports first-quarter ...

26.04.2024
AbbVie Inc.

ABBVIE INC.

AbbVie Reports First-Quarter 2024 Financial Results - Form 8-K

Abbvie reports first-quarter 2024 financial results •reports first-quarter diluted eps of $0.77 on a gaap basis, an increase of 492.3 percent; adjusted diluted eps of $2.31, a de ...

26.04.2024
AbbVie Inc.

ABBVIE INC.

AbbVie Reports First-Quarter 2024 Financial Results

Press release abbvie reports first-quarter 2024 financial results reports first-quarter diluted eps of $0.77 on a gaap basis, an increase of 492.3 percent; adjusted diluted eps of ...

26.04.2024
AbbVie Inc.

ABBVIE INC.

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

Immunology r&d news april 25, 2024 new data show rinvoq® (upadacitinib) demonstrated superiority versus dupixent® (dupilumab) across primary and all secondary endpoints in an ...

25.04.2024
AbbVie Inc.

ABBVIE INC.

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

Immunology r&d news april 18, 2024 phase 3 select-gca study of upadacitinib (rinvoq®) showed positive results in patients with giant cell arteritis open a printable version of ...

18.04.2024
AbbVie Inc.

ABBVIE INC.

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

Neuroscience r&d news april 12, 2024 abbvie announces late-breaking data at aan supporting long-term safety and efficacy of atogepant (qulipta®) for preventive treatment of mi ...

12.04.2024
AbbVie Inc.

ABBVIE INC.

AbbVie to Host First-Quarter 2024 Earnings Conference Call

Corporate news april 04, 2024 abbvie to host first-quarter 2024 earnings conference call open a printable version of this page email the url of this page to a friend north chicago, ...

04.04.2024
Condividi